News articles about Ovid Therapeutc (NASDAQ:OVID) have trended somewhat negative recently, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ovid Therapeutc earned a coverage optimism score of -0.03 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.3821731704103 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Catalyst Advisors Adds New Partner (huntscanlon.com)
- Ovid Therapeutics (OVID) Confirms FDA Orphan Drug Designation for OV101 for Treatment of Fragile X Syndrome (streetinsider.com)
- Ovid Therapeutics Receives Orphan Drug Designation from the U.S. FDA for OV101 for Treatment of Fragile X Syndrome (finance.yahoo.com)
- Ovid Therapeutc (OVID) Given $21.00 Average Target Price by Analysts (americanbankingnews.com)
Shares of Ovid Therapeutc (OVID) opened at 9.24 on Friday. Ovid Therapeutc has a 1-year low of $5.28 and a 1-year high of $15.93. The stock’s market capitalization is $227.31 million. The company has a 50 day moving average price of $8.61 and a 200-day moving average price of $10.05.
Ovid Therapeutc (NASDAQ:OVID) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). On average, equities research analysts forecast that Ovid Therapeutc will post ($3.88) EPS for the current fiscal year.
Separately, Zacks Investment Research downgraded Ovid Therapeutc from a “hold” rating to a “sell” rating in a research note on Wednesday, August 16th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $23.50.
TRADEMARK VIOLATION NOTICE: “Somewhat Negative News Coverage Somewhat Unlikely to Affect Ovid Therapeutc (OVID) Share Price” was posted by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.themarketsdaily.com/2017/10/13/somewhat-negative-news-coverage-somewhat-unlikely-to-affect-ovid-therapeutc-ovid-share-price.html.
In other news, CEO Jeremy M. Levin purchased 15,334 shares of the firm’s stock in a transaction on Friday, August 25th. The stock was purchased at an average cost of $7.15 per share, with a total value of $109,638.10. Following the purchase, the chief executive officer now owns 4,601,529 shares in the company, valued at approximately $32,900,932.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Ovid Therapeutc Company Profile
Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.
Receive News & Ratings for Ovid Therapeutc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutc and related companies with MarketBeat.com's FREE daily email newsletter.